Mylan Pharmaceuticals has begun marketing the first generic version of Sanofi Aventis’ BenzaClin.
The preparation, the first to be approved by the US Food and Drug Administration (FDA), consists of 1% clindamycin and 5% benzoyl peroxide gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International.
Dow received FDA approval for its for clindamycin 1% and benzoyl peroxide 5% gel, a prescription-strength topical antibiotic used to treat acne, on 11 August.
BenzaClin had total US sales of approximately $221m for the 12 months ending 30 June.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData